ProRx Pharma, a health and wellness 503B outsourcing facility, announced on Monday that it has launched four new injectable products -- Sermorelin, NAD+, Glutathione and MIC/B6/B12 -- as part of its expanded health and wellness line.
The new offerings are intended to meet rising demand for preventative treatments among physicians and patients.
Each product is a standalone formulation with its own National Drug Code and Beyond Use Date ranging from 3 to 12 months. Distribution includes bulk shipping to 26 states through partners such as 503A pharmacies, clinics, med spas and telemedicine providers, with direct-to-patient shipping available in all 50 US states.
The newly introduced compounds serve various functions: Sermorelin is a growth hormone peptide, NAD+ is a cellular antioxidant, Glutathione functions as an antioxidant and MIC/B6/B12 is a lipotropic amino acid complex.
This product launch follows ProRx Pharma's February expansion, which doubled its operational footprint to 6,888 sq ft. The facility upgrade has tripled manufacturing capacity and improved compliance capabilities aligned with FDA and compounding lab standards.
Nordic Bioscience launches new Endotrophin assay
Endo adds new concentration to ADRENALIN ready-to-use premixed bag line
OS Therapies launches OS Animal Health to target USD150m canine osteosarcoma market
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
GC Biopharma secures FDA approval for US plasma centre
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software
Benuvia Operations enters Dronabinol API commercial supply agreement with US pharmaceutical company